ANTI-CANCER COMBINATION THERAPIES COMPRISING CTLA-4 AND PD-1 BLOCKING AGENTS

Anti-cancer combination therapies comprising a CTLA-4 blocking agent and a PD-1 blocking agent are disclosed. In particular, combination therapies are disclosed wherein the CTLA-4 blocking agent is an effector-silent anti-CTLA-4 antibody or effector-silent anti-CTLA-4 antibody fragment and the PD-1...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	SAWANT, Anandi, MAUZE, Smita, ANNAMALAI, Lakshmanan, GREIN, Jeffery, BAUCHE, David, LAFACE, Drake, PUNNONEN, Juha, BOWMAN, Edward, CHACKERIAN, Alissa
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Anti-cancer combination therapies comprising a CTLA-4 blocking agent and a PD-1 blocking agent are disclosed. In particular, combination therapies are disclosed wherein the CTLA-4 blocking agent is an effector-silent anti-CTLA-4 antibody or effector-silent anti-CTLA-4 antibody fragment and the PD-1 blocking agent is an anti- PD-1 or anti-PD-L1 antibody, or antibody fragment thereof. L'invention concerne des polythérapies anticancéreuses comprenant un agent de blocage de CTLA-4 et un agent de blocage de PD-1. En particulier, l'invention concerne des polythérapies lors desquelles l'agent de blocage de CTLA-4 est un anticorps anti-CTLA-4 effecteur-silencieux ou un fragment d'anticorps anti-CTLA-4 effecteur-silencieux et l'agent bloquant PD-1 est un anticorps anti-PD-1 ou anti-PD-L1, ou un fragment d'anticorps de celui-ci.